Sign up to save your podcasts
Or
Share Pachychoroid: Current concepts on clinical features and pathogenesis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Pachychoroid: Current concepts on clinical features and pathogenesis
In this episode, Vision Academy members Professor Annabelle Okada, Professor of Ophthalmology and Director of the Ocular Inflammation Service and the Macular Disease Service at the Kyorin University School of Medicine in Japan, and Professor Ian Pearce, Consultant Ophthalmologist and Vitreoretinal Surgeon at the Royal Liverpool University Hospital in the UK, discuss the pachychoroid spectrum.
Using practical examples from their own clinics, they explore how accurate diagnosis, monitoring, prognosis and treatment decisions depend upon consensus descriptions of clinical, morphological and epidemiological characteristics disorders on the pachychoroid spectrum. They also discuss multimodal imaging and barriers to its implementation in clinical practice.
The Vision Academy Viewpoint covering the consensus on the definition of pachychoroid and details on the management of the pathologies included in this spectrum, and other important viewpoints and resources, can be found here. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.
If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing the importance of characterizing macular neovascularization subtypes in nAMD to optimize treatment outcomes, and how we as ophthalmologists can best choose the optimal anti-VEGF therapy regimen for our patients with retinal vascular diseases. SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
Speaker disclosures:
Professor Annabelle Okada
Consultancy: Bayer, Chugai, Novartis, Roche, and Santen Pharmaceutical.
Professor Ian Pearce
Consultancy: Apellis, Bayer, Novartis, and Roche.
Further information on Pachychoroid:
Castro-Navarro V., et al. Pachychoroid: current concepts on clinical features and pathogenesis. Graefes Arch Clin Exp Ophthalmol.2020.
Warrow DJ., Hoang QV. and Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013.
Miyake M., et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep. 2015.
Li Y., et al. Polypoidal choroidal vasculopathy in adult Chinese: the Beijing Eye Study. Ophthalmology. 2014.
Li Y., et al. Prevalence and associations of central serous chorioretinopathy in elderly Chinese. The Beijing Eye Study 2011. Acta Ophthalmol. 2016.
Manayath GJ., et al. Polypoidal choroidal vasculopathy associated with central serous chorioretinopathy: pachychoroid spectrum of diseases. Retina.
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
View all episodes
By ApotheComIn this episode, Vision Academy members Professor Annabelle Okada, Professor of Ophthalmology and Director of the Ocular Inflammation Service and the Macular Disease Service at the Kyorin University School of Medicine in Japan, and Professor Ian Pearce, Consultant Ophthalmologist and Vitreoretinal Surgeon at the Royal Liverpool University Hospital in the UK, discuss the pachychoroid spectrum.
Using practical examples from their own clinics, they explore how accurate diagnosis, monitoring, prognosis and treatment decisions depend upon consensus descriptions of clinical, morphological and epidemiological characteristics disorders on the pachychoroid spectrum. They also discuss multimodal imaging and barriers to its implementation in clinical practice.
The Vision Academy Viewpoint covering the consensus on the definition of pachychoroid and details on the management of the pathologies included in this spectrum, and other important viewpoints and resources, can be found here. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.
If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing the importance of characterizing macular neovascularization subtypes in nAMD to optimize treatment outcomes, and how we as ophthalmologists can best choose the optimal anti-VEGF therapy regimen for our patients with retinal vascular diseases. SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
Speaker disclosures:
Professor Annabelle Okada
Consultancy: Bayer, Chugai, Novartis, Roche, and Santen Pharmaceutical.
Professor Ian Pearce
Consultancy: Apellis, Bayer, Novartis, and Roche.
Further information on Pachychoroid:
Castro-Navarro V., et al. Pachychoroid: current concepts on clinical features and pathogenesis. Graefes Arch Clin Exp Ophthalmol.2020.
Warrow DJ., Hoang QV. and Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013.
Miyake M., et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep. 2015.
Li Y., et al. Polypoidal choroidal vasculopathy in adult Chinese: the Beijing Eye Study. Ophthalmology. 2014.
Li Y., et al. Prevalence and associations of central serous chorioretinopathy in elderly Chinese. The Beijing Eye Study 2011. Acta Ophthalmol. 2016.
Manayath GJ., et al. Polypoidal choroidal vasculopathy associated with central serous chorioretinopathy: pachychoroid spectrum of diseases. Retina.
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.